HLB Innovation Unveils Preclinical Results of Verismo's Solid Tumor CAR-T
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical solid tumor CAR-T data at a conference; early-stage, no revenue size given.
024850 · KOSDAQ · ₩024850 · HLB이노베이션
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−49.5% from the high
₩7,460Today: ₩14,350 – ₩15,400₩29,101
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 26: sell ₩340M at the close (4.5% of 20-day average trading value)
On its 37 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 0.8% of trading value and pointed the same way 4 of 37 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
HLB innoVation (HLB이노베이션, KRX: 024850) is listed on KOSDAQ, in the Electronic components sector. HLB Innovation manufactures semiconductor components, mainly lead frames (including general, pre-mold, and power module types) and contact pins used in chip testing sockets, supplying customers in the global semiconductor assembly and test industry, including automotive, industrial and consumer electronics applications. Its shares closed at ₩14,700 on Oct 27, 2026, down 1.08% on the day, giving it a market value of ₩508B.
HLB Innovation manufactures semiconductor components, mainly lead frames (including general, pre-mold, and power module types) and contact pins used in chip testing sockets, supplying customers in the global semiconductor assembly and test industry, including automotive, industrial and consumer electronics applications. Through its U.S.-based subsidiary Verismo Therapeutics, the company is also developing CAR-T cell therapies, including its KIR-CAR platform aimed at solid tumors and relapsed or refractory blood cancers.
Written by AI from the company's latest annual report.
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical solid tumor CAR-T data at a conference; early-stage, no revenue size given.
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical CAR-T data at a conference; early-stage with no revenue impact.
Titles in Korean until English translations are added.
Also known as: HLB innoVation / HLB이노베이션 / 024850 / KRX:024850
Source: KRX statistical information